Ozempic (semaglutide) is a medication that is used to treat type 2 diabetes. It is in a class of drugs called GLP-1 receptor agonists, which work by increasing the production of insulin in the body and decreasing the amount of glucose produced by the liver. Ozempic is administered once a week via injection and has been shown to be effective in reducing blood sugar levels and aiding in weight loss [1].

Compared to other GLP-1 receptor agonists, Ozempic has a longer half-life, meaning that it stays in the body longer and requires less frequent dosing. For example, Bydureon (exenatide) is another GLP-1 receptor agonist that is administered once a week, but it has a shorter half-life than Ozempic and therefore requires a higher dose [2].

Wegovy (semaglutide) is another medication that is similar to Ozempic. It is also a GLP-1 receptor agonist and is used to treat obesity, rather than diabetes. However, it is important to note that the doses of Wegovy used for obesity treatment are higher than those used for diabetes treatment [3].

Mounjaro (semaglutide) is another GLP-1 receptor agonist that is currently in development. It is being studied for its potential use in treating non-alcoholic steatohepatitis (NASH), a condition that causes inflammation and damage to the liver. However, it is not yet available for use [4].

In summary, Ozempic is a GLP-1 receptor agonist that is used to treat type 2 diabetes. It has a longer half-life than other GLP-1 receptor agonists and requires less frequent dosing. Wegovy is another medication that is similar to Ozempic, but is used to treat obesity rather than diabetes. Mounjaro is a GLP-1 receptor agonist that is currently in development for the treatment of NASH.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/OZEMPIC
[2] https://www.drugs.com/medical-answers/difference-between-ozempic-wegovy-3565564/
[3] https://www.verywellhealth.com/ozempic-vs-wegovy-vs-mounjaro-7368829
[4] https://clinicaltrials.gov/ct2/show/NCT04611169